Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI

Overview

Journal Cancer Microenviron

Publisher Springer

Specialty Oncology

Date 2011 May 28

PMID 21618031

Citations 56

Authors

Vanessa Deschoolmeester

Marc Baay

Filip Lardon

Patrick Pauwels

Marc Peeters

Affiliations

Soon will be listed here.

Abstract

There is growing evidence that both local and systemic inflammatory responses play an important role in the progression of a variety of solid tumors. Colorectal cancer (CRC) results from the cumulative effect of sequential genetic alterations, leading to the expression of tumor-associated antigens possibly inducing a cellular anti-tumor immune response. It is well recognized that cytotoxic lymphocytes (CTLs) constitute one of the most important effector mechanisms of anti-tumor-immunity. However, their potential prognostic influence in CRC remains controversial. In addition, other key players like natural killer cells, tumor associated macrophages and regulatory T cells play an important role in the immune attack against CRC and need further investigation. This review will mainly focus on the role of the adaptive immune system in CRC and particularly in regard to microsatellite instability.

Citing Articles

Parvimonas micra forms a distinct bacterial network with oral pathobionts in colorectal cancer patients.

Lowenmark T, Kohn L, Kellgren T, Rosenbaum W, Bronnec V, Lofgren-Burstrom A J Transl Med. 2024; 22(1):947.

PMID: 39420333 PMC: 11487773. DOI: 10.1186/s12967-024-05720-8.

Unique characteristics of the tumor immune microenvironment in young patients with metastatic colorectal cancer.

Griffith B, Lazarus J, McGue J, Krishnan S, DAngelica M, Shia J Front Immunol. 2023; 14:1289402.

PMID: 38152402 PMC: 10751347. DOI: 10.3389/fimmu.2023.1289402.

Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer - possible implications for immunotherapy.

Edin S, Gylling B, Li X, Stenberg A, Lofgren-Burstrom A, Zingmark C Br J Cancer. 2023; 130(1):143-150.

PMID: 38040818 PMC: 10781968. DOI: 10.1038/s41416-023-02483-9.

The Predictive Value of CD3+/CD8+ Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer.

Liu J, Li J, Luo F, Wu S, Li B, Liu K Curr Oncol. 2023; 30(11):9647-9659.

PMID: 37999119 PMC: 10670477. DOI: 10.3390/curroncol30110699.

Enlarged tumour-draining lymph node with immune-activated profile predict favourable survival in non-metastatic colorectal cancer.

Guan X, Cheng P, Wei R, Li J, Jiao S, Zhao Z Br J Cancer. 2023; 130(1):31-42.

PMID: 37957322 PMC: 10781685. DOI: 10.1038/s41416-023-02473-x.

References

Saurer L, Mueller C . T cell-mediated immunoregulation in the gastrointestinal tract. Allergy. 2009; 64(4):505-19. DOI: 10.1111/j.1398-9995.2009.01965.x. View

Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G . In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009; 27(35):5944-51. DOI: 10.1200/JCO.2008.19.6147. View

Sengupta N, MacFie T, Macdonald T, Pennington D, Silver A . Cancer immunoediting and "spontaneous" tumor regression. Pathol Res Pract. 2009; 206(1):1-8. DOI: 10.1016/j.prp.2009.10.001. View

Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A . Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2009; 138(4):1429-40. DOI: 10.1053/j.gastro.2009.10.057. View

Kang J, Chen J, Lee C, Chang J, Shieh Y . Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J Surg Oncol. 2010; 102(3):242-8. DOI: 10.1002/jso.21617. View

Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboue R, Laurent M . Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol. 2009; 22(9):1186-95. DOI: 10.1038/modpathol.2009.80. View

Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette M, Berrehar F . High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut. 2007; 57(6):772-9. DOI: 10.1136/gut.2007.123794. View

Jass J . Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol. 1986; 39(6):585-9. PMC: 499954. DOI: 10.1136/jcp.39.6.585. View

Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24(33):5313-27. DOI: 10.1200/JCO.2006.08.2644. View

10.

Correale P, Rotundo M, Del Vecchio M, Remondo C, Migali C, Ginanneschi C . Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 2010; 33(4):435-41. PMC: 7322625. DOI: 10.1097/CJI.0b013e3181d32f01. View

11.

Ling K, Pratap S, Bates G, Singh B, Mortensen N, George B . Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun. 2007; 7:7. PMC: 2935744. View

12.

Titu L, Monson J, Greenman J . The role of CD8(+) T cells in immune responses to colorectal cancer. Cancer Immunol Immunother. 2002; 51(5):235-47. PMC: 11034234. DOI: 10.1007/s00262-002-0276-4. View

13.

Yaqub S, Henjum K, Mahic M, Jahnsen F, Aandahl E, Bjornbeth B . Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother. 2007; 57(6):813-21. PMC: 11030670. DOI: 10.1007/s00262-007-0417-x. View

14.

Wagner P, Koch M, Nummer D, Palm S, Galindo L, Autenrieth D . Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol. 2008; 15(8):2310-7. DOI: 10.1245/s10434-008-9971-5. View

15.

Shapira S, Lisiansky V, Arber N, Kraus S . Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins. Expert Opin Investig Drugs. 2010; 19 Suppl 1:S67-77. DOI: 10.1517/13543781003737668. View

16.

Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H . Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer. 2004; 91(9):1711-7. PMC: 2410024. DOI: 10.1038/sj.bjc.6602201. View

17.

Lugli A, Karamitopoulou E, Panayiotides I, Karakitsos P, Rallis G, Peros G . CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009; 101(8):1382-92. PMC: 2768462. DOI: 10.1038/sj.bjc.6605318. View

18.

Bonertz A, Weitz J, Pietsch D, Rahbari N, Schlude C, Ge Y . Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest. 2009; 119(11):3311-21. PMC: 2769188. DOI: 10.1172/JCI39608. View

19.

Khorana A, Ryan C, Cox C, Eberly S, Sahasrabudhe D . Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003; 97(4):960-8. DOI: 10.1002/cncr.11152. View

20.

Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan Y, Bork P . Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer. 2001; 93(1):6-11. DOI: 10.1002/ijc.1298. View